The introduction of immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) or its ligand (PD-L1) has been a groundbreaking treatment approach for the management of advanced NSCLC [7,8,9,10,11]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.